Functional selectivity at the μ-opioid receptor: Implications for understanding opioid analgesia and tolerance

Pharmacological Reviews

Volumn 63, Issue 4, 2011, Pages 1001-1019

  Raehal, Kirsten M ^a   Schmid, Cullen L ^a   Groer, Chad E ^a   Bohn, Laura M ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN 1; BETA ARRESTIN 2; FENTANYL; GUANINE NUCLEOTIDE BINDING PROTEIN; MORPHINE; MU OPIATE RECEPTOR;

ANTINOCICEPTION; HOT PLATE TEST; HUMAN; MORPHINE TOLERANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; REVIEW; SECOND MESSENGER;

ANALGESICS; ANALGESICS, OPIOID; DRUG TOLERANCE; GTP-BINDING PROTEIN REGULATORS; HUMANS; PAIN; RECEPTORS, OPIOID, MU;

EID: 80053588007     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.111.004598     Document Type: Review

References (158)

1. Abbadie C, Gultekin SH, and Pasternak GW (2000a) Immunohistochemical localization of the carboxy terminus of the novel mu opioid receptor splice variant MOR-1C within the human spinal cord. Neuroreport 11:1953-1957.
2. Abbadie C, Pan Y, Drake CT, and Pasternak GW (2000b) Comparative immunohistochemical distributions of carboxy terminus epitopes from the mu-opioid receptor splice variants MOR-1D, MOR-1 and MOR-1C in the mouse and rat CNS. Neuroscience 100:141-153.
3. Abbadie C, Pan YX, and Pasternak GW (2000c) Differential distribution in rat brain of mu opioid receptor carboxy terminal splice variants MOR-1C-like and MOR-1-like immunoreactivity: evidence for region-specific processing. J Comp Neurol 419:244-256.
4. Ahn S, Nelson CD, Garrison TR, Miller WE, and Lefkowitz RJ (2003) Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference. Proc Natl Acad Sci USA 100:1740-1744.
5. Alvarez VA, Arttamangkul S, Dang V, Salem A, Whistler JL, Von Zastrow M, Grandy DK, and Williams JT (2002) Mu-Opioid receptors: ligand-dependent activation of potassium conductance, desensitization, and internalization. J Neurosci 22:5769-5776.
6. Arden JR, Segredo V, Wang Z, Lameh J, and Sadée W (1995) Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged mu-opioid receptor expressed in HEK 293 cells. J Neurochem 65:1636-1645.
7. Arttamangkul S, Quillinan N, Low MJ, von Zastrow M, Pintar J, and Williams JT (2008) Differential activation and trafficking of micro-opioid receptors in brain slices. Mol Pharmacol 74:972-979.
8. Bailey CP, Kelly E, and Henderson G (2004) Protein kinase C activation enhances morphine-induced rapid desensitization of mu-opioid receptors in mature rat locus ceruleus neurons. Mol Pharmacol 66:1592-1598.
9. Bailey CP, Llorente J, Gabra BH, Smith FL, Dewey WL, Kelly E, and Henderson G (2009a) Role of protein kinase C and mu-opioid receptor (MOPr) desensitization in tolerance to morphine in rat locus coeruleus neurons. Eur J Neurosci 29:307-318.
10. Bailey CP, Oldfield S, Llorente J, Caunt CJ, Teschemacher AG, Roberts L, McArdle CA, Smith FL, Dewey WL, Kelly E, et al. (2009b) Involvement of PKC alpha and G-protein-coupled receptor kinase 2 in agonist-selective desensitization of muopioid receptors in mature brain neurons. Br J Pharmacol 158:157-164.
11. Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V, Wetsel WC, Lefkowitz RJ, Gainetdinov RR, and Caron MG (2008) A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132:125-136.
12. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, and Caron MG (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261-273.
13. Bohn LM (2009) Selectivity for G protein or arrestin-mediated signaling, in Functional Selectivity of G Protein-Coupled Receptor Ligands (Neve K ed) pp 71-85, 1st ed, Humana Press, Totowa, NJ.
14. Bohn LM, Dykstra LA, Lefkowitz RJ, Caron MG, and Barak LS (2004) Relative opioid efficacy is determined by the complements of the G protein-coupled receptor desensitization machinery. Mol Pharmacol 66:106-112.
15. Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, and Caron MG (2000) Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408:720-723.
16. Bohn LM, Lefkowitz RJ, and Caron MG (2002) Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. J Neurosci 22:10494-10500.
17. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, and Lin FT (1999) Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 286:2495-2498.
18. Borgland SL, Connor M, Osborne PB, Furness JB, and Christie MJ (2003) Opioid agonists have different efficacy profiles for G protein activation, rapid esensitization, and endocytosis of mu-opioid receptors. J Biol Chem 278:18776-18784.
19. Celver J, Xu M, Jin W, Lowe J, and Chavkin C (2004) Distinct domains of the mu-opioid receptor control uncoupling and internalization. Mol Pharmacol 65: 528-537.
20. Celver JP, Lowe J, Kovoor A, Gurevich VV, and Chavkin C (2001) Threonine 180 is required for G-protein-coupled receptor kinase 3-and beta-arrestin 2-mediated desensitization of the mu-opioid receptor in Xenopus oocytes. J Biol Chem 276: 4894-4900.
21. Chakrabarti S, Law PY, and Loh HH (1998) Distinct differences between morphineand [D-Ala2,N-MePhe4,Gly-ol5]-enkephalin-mu-opioid receptor complexes emonstrated by cyclic AMP-dependent protein kinase phosphorylation. J Neurochem 71:231-239.
22. Chakrabarti S, Prather PL, Yu L, Law PY, and Loh HH (1995) Expression of the mu-opioid receptor in CHO cells: ability of mu-opioid ligands to promote alphaazidoanilido[32P]GTP labeling of multiple G protein alpha subunits. J Neurochem 64:2534-2543.
23. Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V, and Expert Working Group of the European Association of Palliative Care Network (2001) Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 19:2542-2554.
24. Chu J, Zheng H, Loh HH, and Law PY (2008) Morphine-induced mu-opioid receptor rapid desensitization is independent of receptor phosphorylation and betaarrestins. Cell Signal 20:1616-1624.
25. Chu J, Zheng H, Zhang Y, Loh HH, and Law PY (2010) Agonist-dependent mu-opioid receptor signaling can lead to heterologous desensitization. Cell Signal 22:684-696.
26. Clayton CC, Bruchas MR, Lee ML, and Chavkin C (2010) Phosphorylation of the mu-opioid receptor at tyrosine 166 (Tyr3.51) in the DRY motif reduces agonist efficacy. Mol Pharmacol 77:339-347.
27. Collett BJ (1998) Opioid tolerance: the clinical perspective. Br J Anaesth 81:58-68.
28. Crain SM and Shen KF (1995) Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment. Proc Natl Acad Sci USA 92:10540-10544.
29. Crain SM and Shen KF (1996) Modulatory effects of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence. Neurochem Res 21:1347-1351.
30. Daaka Y, Luttrell LM, Ahn S, Della Rocca GJ, Ferguson SS, Caron MG, and Lefkowitz RJ (1998) Essential role for G protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase. J Biol Chem 273:685-688.
31. Dang VC and Williams JT (2005) Morphine-Induced mu-opioid receptor desensitization. Mol Pharmacol 68:1127-1132.
32. Deng HB, Yu Y, Pak Y, O'Dowd BF, George SR, Surratt CK, Uhl GR, and Wang JB (2000) Role for the C-terminus in agonist-induced mu opioid receptor phosphorylation and desensitization. Biochemistry 39:5492-5499.
33. Di Chiara G and Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274-5278.
34. Duttaroy A and Yoburn BC (1995) The effect of intrinsic efficacy on opioid tolerance. Anesthesiology 82:1226-1236.
35. El Kouhen R, Burd AL, Erickson-Herbrandson LJ, Chang CY, Law PY, and Loh HH (2001) Phosphorylation of Ser363, Thr370, and Ser375 residues within the carboxyl tail differentially regulates mu-opioid receptor internalization. J Biol Chem 276:12774-12780.
36. Erdtmann-Vourliotis M, Mayer P, Ammon S, Riechert U, and Höllt V (2001) Distribution of G-protein-coupled receptor kinase (GRK) isoforms 2, 3, 5 and 6 mRNA in the rat brain. Brain research 95:129-137.
37. Fan X, Zhang J, Zhang X, Yue W, and Ma L (2002) Acute and chronic morphine treatments and morphine withdrawal differentially regulate GRK2 and GRK5 gene expression in rat brain. Neuropharmacology 43:809-816.
38. Feng B, Li Z, and Wang JB (2011) Protein kinase C-mediated phosphorylation of the μ-opioid receptor and its effects on receptor signaling. Mol Pharmacol 79:768-775.
39. Ferguson SS (2001) Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53:1-24.
40. Ferguson SS, Downey WE 3rd, Colapietro AM, Barak LS, Ménard L, and Caron MG (1996) Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 271:363-366.
41. Frölich N, Dees C, Paetz C, Ren X, Lohse MJ, Nikolaev VO, and Zenk MH (2011) Distinct pharmacological properties of morphine metabolites at Gi-protein and β-arrestin signaling pathways activated by the human μ-opioid receptor. Biochem Pharm 81:1248-1254.
42. Gabra BH, Bailey CP, Kelly E, Smith FL, Henderson G, and Dewey WL (2008) Pre-treatment with a PKC or PKA inhibitor prevents the development of morphine tolerance but not physical dependence in mice. Brain Res 1217:70-77.
43. Garzón J, Rodríguez-Muñoz M, and Sánchez-Blázquez P (2008) Do pharmacological approaches that prevent opioid tolerance target different elements in the same regulatory machinery? Curr Drug Abuse Rev 1:222-238.
44. Ge X, Qiu Y, Loh HH, and Law PY (2009) GRIN1 regulates micro-opioid receptor activities by tethering the receptor and G protein in the lipid raft. J Biol Chem 284:36521-36534.
45. Granados-Soto V, Kalcheva I, Hua X, Newton A, and Yaksh TL (2000) Spinal PKC activity and expression: role in tolerance produced by continuous spinal morphine infusion. Pain 85:395-404.
46. Grecksch G, Bartzsch K, Widera A, Becker A, Höllt V, and Koch T (2006) Development of tolerance and sensitization to different opioid agonists in rats. Psychopharmacology (Berl) 186:177-184.
47. Groer CE, Tidgewell K, Moyer RA, Harding WW, Rothman RB, Prisinzano TE, and Bohn LM (2007) An opioid agonist that does not induce micro-opioid receptor- arrestin interactions or receptor internalization. Mol Pharmacol 71:549-557.
48. Gurevich VV and Gurevich EV (2006) The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacol Ther 110:465-502.
49. Haberstock-Debic H, Kim KA, Yu YJ, and von Zastrow M (2005) Morphine promotes rapid, arrestin-dependent endocytosis of mu-opioid receptors in striatal neurons. J Neurosci 25:7847-7857.
50. Haberstock-Debic H, Wein M, Barrot M, Colago EE, Rahman Z, Neve RL, Pickel VM, Nestler EJ, von Zastrow M, and Svingos AL (2003) Morphine acutely regulates opioid receptor trafficking selectively in dendrites of nucleus accumbens neurons. J Neurosci 23:4324-4332.
51. Harding WW, Tidgewell K, Byrd N, Cobb H, Dersch CM, Butelman ER, Rothman RB, and Prisinzano TE (2005) Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. J Med Chem 48:4765-4771.
52. Harris JD (2008) Management of expected and unexpected opioid-related side effects. Clin J Pain 24 (Suppl 10):S8-S13.
53. He L and Whistler JL (2005) An opioids cocktail that reduces morphine tolerance and dependence. Curr Biol 15:1028-1033.
54. Hua XY, Moore A, Malkmus S, Murray SF, Dean N, Yaksh TL, and Butler M (2002) Inhibition of spinal protein kinase Calpha expression by an antisense oligonucleotide attenuates morphine infusion-induced tolerance. Neuroscience 113:99-107.
55. Hull LC, Llorente J, Gabra BH, Smith FL, Kelly E, Bailey C, Henderson G, and Dewey WL (2010) The effect of protein kinase C and G protein-coupled receptor kinase inhibition on tolerance induced by mu-opioid agonists of different efficacy. J Pharmacol Exp Ther 332:1127-1135.
56. Inoue M and Ueda H (2000) Protein kinase C-mediated acute tolerance to peripheral mu-opioid analgesia in the bradykinin-nociception test in mice. J Pharmacol Exp Ther 293:662-669.
57. Johnson EA, Oldfield S, Braksator E, Gonzalez-Cuello A, Couch D, Hall KJ, Mundell SJ, Bailey CP, Kelly E, and Henderson G (2006) Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells. Mol Pharmacol 70:676-685.
58. Keith DE, Murray SR, Zaki PA, Chu PC, Lissin DV, Kang L, Evans CJ, and von Zastrow M (1996) Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 271:19021-19024.
59. Kenakin T (2005) New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov 4:919-927.
60. Kenakin T (2007) Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors. Trends Pharmacol Sci 28:407-415.
61. Kenakin T (2009) Biased agonism. F1000 Biol Rep 1:87.
62. Kenakin T (2011) Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 336:296-302.
63. Kieffer BL (1999) Opioids: first lessons from knockout mice. Trends Pharmacol Sci 20:19-26.
64. Koch T, Brandenburg LO, Liang Y, Schulz S, Beyer A, Schröder H, and Höllt V (2004) Phopsholipase D2 modulates agonist-induced mu-opioid receptor desensitization and resensitization. J Neurochem 88:680-688.
65. Koch T, Brandenburg LO, Schulz S, Liang Y, Klein J, and Hollt V (2003) ADPribosylation factor-dependent phospholipase D2 activation is required for agonistinduced mu-opioid receptor endocytosis. J Biol Chem 278:9979-9985.
66. Koch T, Kroslak T, Mayer P, Raulf E, and Höllt V (1997) Site mutation in the rat mu-opioid receptor demonstrates the involvement of calcium/calmodulindependent protein kinase II in agonist-mediated desensitization. J Neurochem 69:1767-1770.
67. Koch T, Schulz S, Pfeiffer M, Klutzny M, Schröder H, Kahl E, and Höllt V (2001) C-terminal splice variants of the mouse mu-opioid receptor differ in morphineinduced internalization and receptor resensitization. J Biol Chem 276:31408-31414.
68. Koch T, Widera A, Bartzsch K, Schulz S, Brandenburg LO, Wundrack N, Beyer A, Grecksch G, and Höllt V (2005) Receptor endocytosis counteracts the development of opioid tolerance. Mol Pharmacol 67:280-287.
69. Kohout TA, Lin FS, Perry SJ, Conner DA, and Lefkowitz RJ (2001) Beta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. Proc Natl Acad Sci USA 98:1601-1606.
70. Kovoor A, Celver JP, Wu A, and Chavkin C (1998) Agonist induced homologous desensitization of mu-opioid receptors mediated by G protein-coupled receptor kinases is dependent on agonist efficacy. Mol Pharmacol 54:704-711.
71. Kramer HK and Simon EJ (1999) Role of protein kinase C (PKC) in agonist-induced mu opioid receptor down-regulation: I. PKC translocation to the membrane of SH-SY5Y neuroblastoma cells is induced by mu-opioid agonists. J Neurochem 72:585-593.
72. Kreek MJ (1973) Medical safety and side effects of methadone in tolerant individuals. JAMA 223:665-668.
73. Kumar P, Sunkaraneni S, Sirohi S, Dighe SV, Walker EA, and Yoburn BC (2008) Hydromorphone efficacy and treatment protocol impact on tolerance and muopioid receptor regulation. Eur J Pharmacol 597:39-45.
74. Law PY (2011) Opioid receptor signal transduction mechanisms, in The Opioid Receptors (Pasternak GW ed) pp 195-237, Springer Science, New York.
75. Li Y, Liu X, Liu C, Kang J, Yang J, Pei G, and Wu C (2009) Improvement of morphine-mediated analgesia by inhibition of beta-arrestin 2 expression in mice periaqueductal gray matter. Int J Mol Sci 10:954-963.
76. Lin FT, Daaka Y, and Lefkowitz RJ (1998) Beta-arrestins regulate mitogenic signaling and clathrin-mediated endocytosis of the insulin-like growth factor 1 receptor. J Biol Chem 273:31640-31643.
77. Luttrell LM, Daaka Y, Della Rocca GJ, and Lefkowitz RJ (1997) G protein-coupled receptors mediate two functionally distinct pathways of tyrosine phosphorylation in rat 1a fibroblasts. Shc phosphorylation and receptor endocytosis correlate with activation of Erk kinases. J Biol Chem 272:31648-31656.
78. Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, Lin F, Kawakatsu H, Owada K, Luttrell DK, et al. (1999) Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283: 655-661.
79. Luttrell LM and Lefkowitz RJ (2002) The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 115:455-465.
80. Macey TA, Lowe JD, and Chavkin C (2006) Mu opioid receptor activation of ERK1/2 is GRK3 and arrestin dependent in striatal neurons. J Biol Chem 281:34515-34524.
81. Madia PA, Dighe SV, Sirohi S, Walker EA, and Yoburn BC (2009) Dosing protocol and analgesic efficacy determine opioid tolerance in the mouse. Psychopharmacology (Berl) 207:413-422.
82. Maher CE, Eisenach JC, Pan HL, Xiao R, and Childers SR (2001) Chronic intrathecal morphine administration produces homologous mu receptor/G-protein desensitization specifically in spinal cord. Brain Res 895:1-8.
83. Mailman RB (2007) GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci 28:390-396.
84. Massotte D, Brillet K, Kieffer B, and Milligan G (2002) Agonists activate Gi1 alpha or Gi2 alpha fused to the human mu opioid receptor differently. J Neurochem 81:1372-1382.
85. McDonald PH, Chow CW, Miller WE, Laporte SA, Field ME, Lin FT, Davis RJ, and Lefkowitz RJ (2000) Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 290:1574-1577.
86. McPherson J, Rivero G, Baptist M, Llorente J, Al-Sabah S, Krasel C, Dewey WL, Bailey CP, Rosethorne EM, Charlton SJ, et al. (2010) Mu-Opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol 78:756-766.
87. Melief EJ, Miyatake M, Bruchas MR, and Chavkin C (2010) Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc Natl Acad Sci USA 107:11608-11613.
88. Melnikova I (2010) Pain market. Nat Rev Drug Discov 9:589-590.
89. Molinari P, Vezzi V, Sbraccia M, Gro C, Riitano D, Ambrosio C, Casella I, and Costa T (2010) Morphine-like opioids selectively antagonize receptor-arrestin interactions. J Biol Chem 285:12522-12535.
90. Narita M, Mizoguchi H, Suzuki T, Narita M, Dun NJ, Imai S, Yajima Y, Nagase H, Suzuki T, and Tseng LF (2001) Enhanced mu-opioid responses in the spinal cord of mice lacking protein kinase Cgamma isoform. J Biol Chem 276:15409-15414.
91. Narita M, Narita M, Mizoguchi H, and Tseng LF (1995) Inhibition of protein kinase C, but not of protein kinase A, blocks the development of acute antinociceptive tolerance to an intrathecally administered mu-opioid receptor agonist in the mouse. Eur J Pharmacol 280:R1-R3.
92. Noble F and Cox BM (1996) Differential desensitization of mu-and delta-opioid receptors in selected neural pathways following chronic morphine treatment. Br J Pharmacol 117:161-169.
93. Oakley RH, Laporte SA, Holt JA, Barak LS, and Caron MG (1999) Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J Biol Chem 274:32248-32257.
94. Oakley RH, Laporte SA, Holt JA, Caron MG and Barak LS (2000) Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G proteincoupled receptors delineate two major classes of receptors. J Biol Chem 275: 17201-17210.
95. Pak Y, O'Dowd BF, and George SR (1997) Agonist-induced desensitization of the mu opioid receptor is determined by threonine 394 preceded by acidic amino acids in the COOH-terminal tail. J Biol Chem 272:24961-24965.
96. Pan YX, Xu J, Bolan E, Abbadie C, Chang A, Zuckerman A, Rossi G, and Pasternak GW (1999) Identification and characterization of three new alternatively spliced mu-opioid receptor isoforms. Mol Pharmacol 56:396-403.
97. Patel MB, Patel CN, Rajashekara V, and Yoburn BC (2002) Opioid agonists differentially regulate mu-opioid receptors and trafficking proteins in vivo. Mol Pharmacol 62:1464-1470.
98. Pawar M, Kumar P, Sunkaraneni S, Sirohi S, Walker EA, and Yoburn BC (2007) Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of mu-opioid receptors and dynamin-2. Eur J Pharmacol 563:92-101.
99. Polakiewicz RD, Schieferl SM, Dorner LF, Kansra V, and Comb MJ (1998) A mitogen-activated protein kinase pathway is required for mu-opioid receptor desensitization. J Biol Chem 273:12402-12406.
100. Premont RT and Gainetdinov RR (2007) Physiological roles of G protein-coupled receptor kinases and arrestins. Annu Rev Physiol 69:511-534.
101. Premont RT, Macrae AD, Stoffel RH, Chung N, Pitcher JA, Ambrose C, Inglese J, MacDonald ME, and Lefkowitz RJ (1996) Characterization of the G proteincoupled receptor kinase GRK4. Identification of four splice variants. J Biol Chem 271:6403-6410.
102. Przewlocka B, Sieja A, Starowicz K, Maj M, Bilecki W, and Przewlocki R (2002) Knockdown of spinal opioid receptors by antisense targeting beta-arrestin reduces morphine tolerance and allodynia in rat. Neurosci Lett 325:107-110.
103. Quillan JM, Carlson KW, Song C, Wang D, and Sadée W (2002) Differential effects of mu-opioid receptor ligands on Ca2_ signaling. J Pharmacol Exp Ther 302:1002-1012.
104. Quillinan N, Lau EK, Virk M, von Zastrow M, and Williams JT (2011) Recovery from_-opioid receptor desensitization after chronic treatment with morphine and methadone. J Neurosci 31:4434-4443.
105. Raehal KM and Bohn LM (2005) Mu opioid receptor regulation and opioids responsiveness. AAPS J 7:E587-E591.
106. Raehal KM and Bohn LM (2011) The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology 60:58-65.
107. Raehal KM, Schmid CL, Medvedev IO, Gainetdinov RR, Premont RT, and Bohn LM (2009) Morphine-induced physiological and behavioral responses in mice lacking G protein-coupled receptor kinase 6. Drug Alcohol Depend 104:187-196.
108. Robinson TE and Berridge KC (2000) The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 95:S91-S117.
109. Rozenfeld R and Devi LA (2007) Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. FASEB J 21:2455-2465.
110. Saidak Z, Blake-Palmer K, Hay DL, Northup JK, and Glass M (2006) Differential activation of G-proteins by mu-opioid receptor agonists. Br J Pharmacol 147:671-680.
111. Sanada H, Yatabe J, Midorikawa S, Katoh T, Hashimoto S, Watanabe T, Xu J, Luo Y, Wang X, Zeng C, et al. (2006) Amelioration of genetic hypertension by suppression of renal G protein-coupled receptor kinase type 4 expression. Hypertension 47:1131-1139.
112. Sánchez-Blázquez P, García-España A, and Garzón J (1995) In vivo injection of antisense oligodeoxynucleotides to G alpha subunits and supraspinal analgesia evoked by mu and delta opioid agonists. J Pharmacol Exp Ther 275:1590-1596.
113. Sánchez-Blázquez P, Gómez-Serranillos P, and Garzón J (2001) Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia. Brain Res Bull 54:229-235.
114. Sánchez-Blázquez P, Rodríguez-Díaz M, DeAntonio I, and Garzón J (1999) Endomorphin-1 and endomorphin-2 show differences in their activation of mu opioid receptor-regulated G proteins in supraspinal antinociception in mice. J Pharmacol Exp Ther 291:12-18.
115. Scherrer G, Imamachi N, Cao YQ, Contet C, Mennicken F, O'Donnell D, Kieffer BL, and Basbaum AI (2009) Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell 137:1148-1159.
116. Schmid CL and Bohn LM (2009) Physiological and pharmacological implications of beta-arrestin regulation. Pharmacol Ther 121:285-293.
117. Schmid CL and Bohn LM (2010) Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a μ-arrestin2/Src/Akt signaling complex in vivo. J Neurosci 30:13513-13524.
118. Schmid CL, Raehal KM, and Bohn LM (2008) Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci USA 105:1079-1084.
119. Schulz S, Mayer D, Pfeiffer M, Stumm R, Koch T, and Höllt V (2004) Morphine induces terminal micro-opioid receptor desensitization by sustained phosphorylation of serine-375. EMBO J 23:3282-3289.
120. Sim LJ, Selley DE, Dworkin SI, and Childers SR (1996) Effects of chronic morphine administration on mu opioid receptor-stimulated [35S]GTPgammaS autoradiography in rat brain. J Neurosci 16:2684-2692.
121. Sim-Selley LJ, Scoggins KL, Cassidy MP, Smith LA, Dewey WL, Smith FL, and Selley DE (2007) Region-dependent attenuation of mu opioid receptor-mediated G-protein activation in mouse CNS as a function of morphine tolerance. Br J Pharmacol 151:1324-1333.
122. Sim-Selley LJ, Selley DE, Vogt LJ, Childers SR, and Martin TJ (2000) Chronic heroin self-administration desensitizes mu opioid receptor-activated G-proteins in specific regions of rat brain. J Neurosci 20:4555-4562.
123. Sirohi S, Dighe SV, Walker EA, and Yoburn BC (2008) The analgesic efficacy of fentanyl: relationship to tolerance and mu-opioid receptor regulation. Pharmacol Biochem Behav 91:115-120.
124. Smith FL, Javed R, Elzey MJ, Welch SP, Selley D, Sim-Selley L, and Dewey WL (2002) Prolonged reversal of morphine tolerance with no reversal of dependence by protein kinase C inhibitors. Brain Res 958:28-35.
125. Smith FL, Javed RR, Elzey MJ, and Dewey WL (2003) The expression of a high level of morphine antinociceptive tolerance in mice involves both PKC and PKA. Brain Res 985:78-88.
126. Stafford K, Gomes AB, Shen J, and Yoburn BC (2001) Mu-Opioid receptor downregulation contributes to opioid tolerance in vivo. Pharmacol Biochem Behav 69:233-237.
127. Sternini C, Spann M, Anton B, Keith DE Jr, Bunnett NW, von Zastrow M, Evans C, and Brecha NC (1996) Agonist-selective endocytosis of mu opioid receptor by neurons in vivo. Proc Natl Acad Sci USA 93:9241-9246.
128. Stevens CW and Yaksh TL (1989) Potency of infused spinal antinociceptive agents is inversely related to magnitude of tolerance after continuous infusion. J Pharmacol Exp Ther 250:1-8.
129. Terman GW, Jin W, Cheong YP, Lowe J, Caron MG, Lefkowitz RJ, and Chavkin C (2004) G-protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal. Br J Pharmacol 141:55-64.
130. Tidgewell K, Groer CE, Harding WW, Lozama A, Schmidt M, Marquam A, Hiemstra J, Partilla JS, Dersch CM, Rothman RB, et al. (2008) Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem 51:2421-2431.
131. Ueda H, Inoue M, and Matsumoto T (2001) Protein kinase C-mediated inhibition of mu-opioid receptor internalization and its involvement in the development of acute tolerance to peripheral mu-agonist analgesia. J Neurosci 21:2967-2973.
132. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. (2007) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13.
133. Urs NM, Daigle TL, and Caron MG (2010) A dopamine D1 receptor-dependent beta- arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice. Neuropsychopharmacology 36:551-558.
134. Van Bockstaele EJ and Commons KG (2001) Internalization of mu-opioid receptors produced by etorphine in the rat locus coeruleus. Neuroscience 108:467-477.
135. Violin JD and Lefkowitz RJ (2007) Beta-arrestin-biased ligands at seventransmembrane receptors. Trends Pharmacol Sci 28:416-422.
136. Virk MS and Williams JT (2008) Agonist-specific regulation of mu-opioid receptor desensitization and recovery from desensitization. Mol Pharmacol 73:1301-1308.
137. Walker EA and Young AM (2001) Differential tolerance to antinociceptive effects of mu opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats. Psychopharmacology (Berl) 154:131-142.
138. Walwyn W, Evans CJ, and Hales TG (2007) Beta-arrestin2 and c-Src regulate the constitutive activity and recycling of mu opioid receptors in dorsal root ganglion neurons. J Neurosci 27:5092-5104.
139. Wang D, Sadée W, and Quillan JM (1999) Calmodulin binding to G protein-coupling domain of opioid receptors. J Biol Chem 274:22081-22088.
140. Wang HL (2000) A cluster of Ser/Thr residues at the C-terminus of mu-opioid receptor is required for G protein-coupled receptor kinase 2-mediated desensitization. Neuropharmacology 39:353-363.
141. Wang HL, Chang WT, Hsu CY, Huang PC, Chow YW, and Li AH (2002) Dentification of two C-terminal amino acids, Ser(355) and Thr(357), required for short-term homologous desensitization of mu-opioid receptors. Biochem Pharmacol 64:257-266.
142. Wang HY and Burns LH (2006) Gbetagamma that interacts with adenylyl cyclase in opioid tolerance originates from a Gs protein. J Neurobiol 66:1302-1310.
143. Wang HY, Friedman E, Olmstead MC, and Burns LH (2005) Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. Neuroscience 135:247-261.
144. Whistler JL and von Zastrow M (1998) Morphine-activated opioid receptors elude desensitization by beta-arrestin. Proc Natl Acad Sci USA 95:9914-9919.
145. Whistler JL, Chuang HH, Chu P, Jan LY, and von Zastrow M (1999) Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23:737-746.
146. Williams JT, Christie MJ, and Manzoni O (2001) Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev 81:299-343.
147. Wolf R, Koch T, Schulz S, Klutzny M, Schröder H, Raulf E, Bü hling F, and Höllt V (1999) Replacement of threonine 394 by alanine facilitates internalization and resensitization of the rat mu opioid receptor. Mol Pharmacol 55:263-268.
148. Xu H, Partilla JS, Wang X, Rutherford JM, Tidgewell K, Prisinzano TE, Bohn LM, and Rothman RB (2007) A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence. Synapse 61:166-175.
149. Yoburn BC, Purohit V, Patel K, and Zhang Q (2004) Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin- 2 in vivo. Eur J Pharmacol 498:87-96.
150. Yu Y, Zhang L, Yin X, Sun H, Uhl GR, and Wang JB (1997) Mu opioid receptor phosphorylation, desensitization, and ligand efficacy. J Biol Chem 272:28869-28874.
151. Yuen EY, Jiang Q, Chen P, Feng J, and Yan Z (2008) Activation of 5-HT2A/C receptors counteracts 5-HT1A regulation of N-methyl-D-aspartate receptor channels in pyramidal neurons of prefrontal cortex. J Biol Chem 283:17194-171204.
152. Zeitz KP, Malmberg AB, Gilbert H, and Basbaum AI (2001) Reduced development of tolerance to the analgesic effects of morphine and clonidine in PKC gamma mutant mice. Pain 94:245-253.
153. Zhang J, Ferguson SS, Barak LS, Bodduluri SR, Laporte SA, Law PY, and Caron MG (1998) Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. Proc Natl Acad Sci USA 95:7157-7162.
154. Zheng H, Chu J, Qiu Y, Loh HH, and Law PY (2008a) Agonist-selective signaling is determined by the receptor location within the membrane domains. Proc Natl Acad Sci USA 105:9421-9426.
155. Zheng H, Chu J, Zeng Y, Loh HH, and Law PY (2010a) Yin Yang 1 phosphorylation contributes to the differential effects of mu-opioid receptor agonists on microRNA- 190 expression. J Biol Chem 285:21994-22002.
156. Zheng H, Chu J, Zhang Y, Loh HH, and Law PY (2011) Modulating _-opioid receptor phosphorylation switches agonist-dependent signaling as reflected in PCK_activation and dendritic spine stability. J Biol Chem 286:12724-12733.
157. Zheng H, Loh HH, and Law PY (2008b) Beta-arrestin-dependent mu-opioid receptoractivated extracellular signal-regulated kinases (ERKs) translocate to nucleus in contrast to G protein-dependent ERK activation. Mol Pharmacol 73:178-190.
158. Zheng H, Zeng Y, Zhang X, Chu J, Loh HH, and Law PY (2010b) Mu-Opioid receptor agonists differentially regulate the expression of miR-190 and NeuroD. Mol Pharmacol 77:102-109.